The UK and US have agreed to a key commercial pact that will maintain zero import taxes on UK pharmaceutical shipments being sold in the US market.
Agreement Details of the Deal
In exchange for the tariff guarantee, the UK has pledged to raise funding on drugs through the public health system. This move secures that import taxes on these vital products will stay at nothing for a period of three years.
This deal follows previous warnings to hike import taxes on patented pharmaceutical imports, with figures floated up to 100%.
"This agreement between the United Kingdom bolsters the worldwide climate for new treatments and introduces much-needed equity to American-British pharmaceutical trade," an announcement said.
Trade Importance
Pharmaceuticals are one of the Britain's largest goods shipped to the United States, which is clearly the primary market for large companies like GSK and AstraZeneca.
Trade data indicate that in the 12 months to the end of last September, the UK shipped drugs totaling £11.1bn to the US. This value made up 17.4% of all goods exports in that span.
"This guarantee secures jobs, boosts capital expenditure and sets the stage for the UK to become a global hub for medical research," a minister stated.
Specific NHS Changes
The pact includes several specific changes from the UK:
- Higher Cost Ceiling: The UK will raise the cost ceiling at which it deems new treatments to be too expensive by twenty-five percent.
- Increased NHS Spending: There is a goal to double total health service expenditure on treatments from 0.3% of GDP to 0.6% over the following ten-year period.
- Refund Ceiling: The percentage pharmaceutical firms must refund to the NHS to control costs will be capped at 15%. Last year, rebates topped 20%.
Industry Background
This agreement follows a protracted dispute between the drug companies and the ministers over spending levels and regulatory access.
This friction were intensified by arguments that US consumers were charged significantly more for the identical medicines than consumers in the other developed nations.
Recently, several large drug company projects in the UK have been halted or abandoned, while substantial expansions have been directed toward American operations.
A senior figure acknowledged that the NHS had to spend more on medicines, noting that its spending on drugs had declined as a percentage of its overall budget over the past decade.
